Payment overview · 2025
General Payments
$587.93
20 reported records · 9 companies
Healthcare provider profile · identity verified
Padma Sripada, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CASTLETON, NY · NPI 1881644755
Verified facts
What the public records show
CMS Open Payments records show Padma Sripada, MD received $587.93 in general payments during 2025 across 20 reported records.
AstraZeneca Pharmaceuticals LP accounted for 30.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 162 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 162 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $179.43 | 30.5% | 7 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $115.20 | 19.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $73.29 | 12.5% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $67.34 | 11.4% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $55.86 | 9.5% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.00 | 5.6% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.01 | 3.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $21.33 | 3.6% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $20.47 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $587.93 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $159.48 | 6 | 2025 |
Source payment records
|
|||||
| Repatha Normalized: repatha |
Biological | Amgen Inc. | $115.20 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $67.34 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $55.86 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $51.20 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $46.87 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $22.09 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $22.09 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $22.01 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $21.45 | 1 | 2025 |
Source payment records
|
|||||
| VARIVAX Normalized: varivax |
Biological | Merck Sharp & Dohme LLC | $21.45 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $21.33 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $20.47 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $19.95 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 106 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
106 | 20 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
162 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
162 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
59 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 515 | 144 |
| Amlodipine Besylate | Amlodipine Besylate | 442 | 101 |
| Eliquis | Apixaban | 406 | 45 |
| Levothyroxine Sodium | Levothyroxine Sodium | 351 | 88 |
| Metoprolol Succinate | Metoprolol Succinate | 292 | 77 |
| Lisinopril | Lisinopril | 240 | 56 |
| Metformin Hcl | Metformin Hcl | 218 | 52 |
| Gabapentin | Gabapentin | 205 | 48 |
| Losartan Potassium | Losartan Potassium | 196 | 55 |
| Jardiance | Empagliflozin | 162 | 26 |
| Omeprazole | Omeprazole | 157 | 48 |
| Sertraline Hcl | Sertraline Hcl | 155 | 41 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 152 | 47 |
| Pantoprazole Sodium | Pantoprazole Sodium | 146 | 45 |
| Carvedilol | Carvedilol | 135 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 126 | 32 |
| Furosemide | Furosemide | 124 | 32 |
| Fluoxetine Hcl | Fluoxetine Hcl | 123 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 107 | 25 |
| Farxiga | Dapagliflozin Propanediol | 106 | 20 |
| Mirtazapine | Mirtazapine | 101 | 20 |
| Prednisone | Prednisone | 86 | 25 |
| Oxycodone Hcl | Oxycodone Hcl | 85 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 84 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 83 | 22 |
| Potassium Chloride | Potassium Chloride | 79 | 23 |
| Finasteride | Finasteride | 74 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 73 | 25 |
| Trazodone Hcl | Trazodone Hcl | 70 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 69 | 29 |
| Tizanidine Hcl | Tizanidine Hcl | 69 | 13 |
| Donepezil Hcl | Donepezil Hcl | 68 | 12 |
| Xifaxan | Rifaximin | 68 | suppressed |
| Olanzapine | Olanzapine | 66 | 14 |
| Celecoxib | Celecoxib | 64 | 14 |
| Memantine Hcl | Memantine Hcl | 63 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 61 | suppressed |
| Trulicity | Dulaglutide | 59 | suppressed |
| Bupropion Xl | Bupropion Hcl | 58 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 58 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 55 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 55 | 15 |
| Glipizide Er | Glipizide | 55 | 12 |
| Latanoprost | Latanoprost | 55 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 50 | 13 |
| Januvia | Sitagliptin Phosphate | 49 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 48 | 29 |
| Atenolol | Atenolol | 46 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 46 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 46 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 45 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 45 | 12 |
| Simvastatin | Simvastatin | 44 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | 18 |
| Allopurinol | Allopurinol | 42 | 16 |
| Baclofen | Baclofen | 42 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 42 | 12 |
| Clonazepam | Clonazepam | 42 | 11 |
| Ezetimibe | Ezetimibe | 42 | 15 |
| Tramadol Hcl | Tramadol Hcl | 42 | 20 |
| Benazepril Hcl | Benazepril Hcl | 41 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 41 | 14 |
| Meclizine Hcl | Meclizine Hcl | 40 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 40 | 12 |
| Levetiracetam | Levetiracetam | 36 | 11 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 35 | 35 |
| Irbesartan | Irbesartan | 35 | suppressed |
| Valsartan | Valsartan | 35 | suppressed |
| Azithromycin | Azithromycin | 34 | 24 |
| Famotidine | Famotidine | 34 | 16 |
| Alprazolam | Alprazolam | 33 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 33 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 33 | suppressed |
| Novolog Flexpen | Insulin Aspart | 32 | suppressed |
| Spironolactone | Spironolactone | 32 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 31 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 31 | 11 |
| Bumetanide | Bumetanide | 30 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 29 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 29 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 28 | 17 |
| Olanzapine Odt | Olanzapine | 28 | suppressed |
| Ozempic | Semaglutide | 28 | suppressed |
| Admelog Solostar | Insulin Lispro | 27 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 21 |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Cephalexin | Cephalexin | 27 | 24 |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 26 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 26 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 25 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 24 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Mounjaro | Tirzepatide | 24 | suppressed |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Telmisartan | Telmisartan | 24 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 23 | suppressed |
| Fluconazole | Fluconazole | 23 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 23 | 13 |
| Ceftriaxone | Ceftriaxone Sodium | 22 | 13 |
| Lorazepam | Lorazepam | 22 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 18 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | 17 |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Oxycontin | Oxycodone Hcl | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 14 |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 18 | 14 |
| Sucralfate | Sucralfate | 18 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 17 | 17 |
| Amantadine | Amantadine Hcl | 17 | suppressed |
| Amoxicillin | Amoxicillin | 17 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 17 | suppressed |
| Exemestane | Exemestane | 17 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 17 | suppressed |
| Meloxicam | Meloxicam | 17 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 17 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 16 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 16 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Rexulti | Brexpiprazole | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Gralise | Gabapentin | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Scopolamine | Scopolamine | 12 | 11 |
| Sodium Chloride | Sodium Chloride Irrig Solution | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Anastrozole | Anastrozole | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $587.93 · 20 records | AstraZeneca Pharmaceuticals LP | BREZTRI, CAPVAXIVE, FARXIGA, GARDASIL 9, KISUNLA, Kerendia, M-M-R II, MOUNJARO, Repatha, The Cologuard Plus Collection Kit, VARIVAX, VOQUEZNA, YUPELRI, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error